Table 2 IL-10 (-1082G/A and -819C/T) genotype distribution and allelic frequency in healthy controls and patients with ovarian cancer
From: Gene polymorphisms of interleukin 10 (− 819 C/T and − 1082 G/A) in women with ovarian cancer
Cytokine gene | Control (N = 48) | Ovarian cancer (N = 48) | P value | OR(95%CI) | AAIC | BBIC |
|---|---|---|---|---|---|---|
IL-10 (-1082 G > A) Genotype (N, %) | ||||||
Codominant model (GA, AA vs GG) GG | 8 (16.7%) | 16 (33.3%) | P < 0.05 | 1.00 | 131 | 136.2 |
GA | 27 (56.2%) | 28 (58.3%) | NS | 0.52 (0.19–1.41) | ||
AA | 13 (27.1%) | 4 (8.3%) | P < 0.05 | 0.15 (0.04–0.63) | ||
Dominant model (GA + AA vs GG) GA + AA | 40 (83.3%) | 32 (66.7%) | NS | 0.40 (0.15–1.05) | ||
Recessive model (AA vs GG + GA) GG + GA | 35 (72.9%) | 44 (91.7%) | P < 0.05 | 1.00 | ||
AA | 13 (27.1%) | 4 (8.3%) | P < 0.05 | 0.24 (0.07–0.82) | ||
Allele frequency (N, %) | ||||||
G | 43 (45.0%) | 60 (62.0%) | P < 0.05 | 2.054 (1.154–3.657) | ||
A | 53 (55.0%) | 36 (38.0%) | P < 0.05 | 0.487 (0.273–0.867) | ||
IL-10 (-819 C/T) genotype (N, %) | ||||||
Codominant model (CT, TT vs CC) CC | 20 (41.7%) | 3 (6.2%) | P < 0.001 | 1.00 | 119 | 124.1 |
CT | 24 (50.0%) | 34 (70.8%) | P < 0.001 | 9.44 (2.52–35.40) | ||
TT | 4 (8.3%) | 11 (22.9%) | P < 0.001 | 18.33 (3.46–97.20) | ||
Dominant model (CT + TT vs CC) CT + TT | 28 (58.3%) | 45 (93.8%) | P < 0.001 | 10.71(2.91–39.39) | ||
Recessive model (TT vs CC + CT) CC + CT | 44 (91.7%) | 37 (77.1%) | P < 0.05 | 1.00 | ||
TT | 4 (8.3%) | 11 (22.9%) | P < 0.05 | 3.27 (0.96–11.13) | ||
Allele frequency (N, %) | ||||||
C | 64 (67.0%) | 40 (42.0%) | P < 0.05 | 0.357 (0.199–0.642) | ||
T | 32 (33.0%) | 56 (58.0%) | P < 0.05 | 2.800 (1.577–5.037) | ||